Treatment with cardiac electronic implantable devices
Herz. 2024 May 6. doi: 10.1007/s00059-024-05246-1. Online ahead of print.ABSTRACTCardiac device therapy provides not only treatment options for bradyarrhythmia but also advanced treatment for heart failure and preventive measures against sudden cardiac death. In heart failure treatment it enables synergistic reverse remodelling and reduces pharmacological side effects. Cardiac resynchronization therapy (CRT) has revolutionized the treatment of reduced left ventricular ejection fraction (LVEF) and left bundle branch block by decreasing the mortality and morbidity with improvement of the quality of life and resilience. Condu...
Source: Hamostaseologie - May 6, 2024 Category: Hematology Authors: J ürgen Kuschyk Katherine Sattler Fabian Fastenrath Boris Rudic Ibrahim Akin Source Type: research
Treatment with cardiac electronic implantable devices
Herz. 2024 May 6. doi: 10.1007/s00059-024-05246-1. Online ahead of print.ABSTRACTCardiac device therapy provides not only treatment options for bradyarrhythmia but also advanced treatment for heart failure and preventive measures against sudden cardiac death. In heart failure treatment it enables synergistic reverse remodelling and reduces pharmacological side effects. Cardiac resynchronization therapy (CRT) has revolutionized the treatment of reduced left ventricular ejection fraction (LVEF) and left bundle branch block by decreasing the mortality and morbidity with improvement of the quality of life and resilience. Condu...
Source: Hamostaseologie - May 6, 2024 Category: Hematology Authors: J ürgen Kuschyk Katherine Sattler Fabian Fastenrath Boris Rudic Ibrahim Akin Source Type: research
Current Topics from the Revised German S2k Guideline on Diagnosis and Treatment of Venous Thromboembolism
Hamostaseologie. 2024 Apr;44(2):90-92. doi: 10.1055/a-2239-0770. Epub 2024 Apr 30.ABSTRACTIt is an honor and a great pleasure for us to be guest editors for this special issue of Hämostaseologie - Progress in Haemostasis, which addresses important issues surrounding the complex of venous thromboembolism (VTE). In February 2023, the revised guideline on "Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism" has been published on the website of the Association of the Scientific Medical Societies in Germany (AWMF)1. This guideline was drawn up under the leadership of the German Society of Angiology (DGA), and ...
Source: Hamostaseologie - April 30, 2024 Category: Hematology Authors: Birgit Linnemann Robert Klamroth Source Type: research
Thrombozyten: Blutstillung ohne Gerinnselbildung
Hamostaseologie. 2024 Apr;44(2):94. doi: 10.1055/a-2280-1098. Epub 2024 Apr 30.ABSTRACTIM VORLIEGENDEN REVIEW FASSEN R. KAISER UND KOLLEGEN BEREITS ANERKANNTE UND NEUERE STUDIEN ZUSAMMEN, DIE ERLäUTERN, WIE ES DEN KLEINEN, KERNLOSEN THROMBOZYTEN GELINGT, DIE VASKULäRE INTEGRITäT AUFRECHTZUERHALTEN, WENN SIE MIT HERAUSFORDERUNGEN WIE INFEKTIONEN, STERILEN ENTZüNDUNGEN UND SOGAR MALIGNITäT KONFRONTIERT WERDEN.PMID:38688266 | DOI:10.1055/a-2280-1098 (Source: Hamostaseologie)
Source: Hamostaseologie - April 30, 2024 Category: Hematology Source Type: research
Efgartigimod hilft bei Immunthrombozytopenie
Hamostaseologie. 2024 Apr;44(2):96. doi: 10.1055/a-2280-1083. Epub 2024 Apr 30.ABSTRACTDIE PRIMäRE IMMUNTHROMBOZYTOPENIE (ITP) IST EINE ERWORBENE AUTOIMMUNERKRANKUNG DURCH AUTOANTIKöRPER GEGEN THROMBOZYTäRE ANTIGENE UND GEKENNZEICHNET DURCH EINE ISOLIERTE THROMBOZYTOPENIE. EFGARTIGIMOD BINDET DEN FC-REZEPTOR KOMPETITIV UND BEWIRKT EINEN ABBAU UND DIE REDUKTION ZIRKULIERENDER IGG-AUTOANTIKöRPER. IN DER PHASE-3-ADVANCE-IV-STUDIE PROFITIERTEN VORBEHANDELTE ERKRANKTE MIT CHRONISCHER UND PERSISTIERENDER ITP.PMID:38688267 | DOI:10.1055/a-2280-1083 (Source: Hamostaseologie)
Source: Hamostaseologie - April 30, 2024 Category: Hematology Source Type: research
Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2024 Apr;44(2):97-110. doi: 10.1055/a-2178-6574. Epub 2024 Apr 30.ABSTRACTDeep vein thrombosis (DVT) and pulmonary embolism (PE) are the most common manifestations of venous thromboembolism (VTE). Most DVTs affect the lower-extremity veins. Since the symptoms of DVT are non-specific, a prompt and standardised diagnostic work-up is essential to minimise the risk of PE in the acute phase and to prevent thrombosis progression, post-thrombotic syndrome and VTE recurrence in the long-term. Only recently, the AWMF S2k guidelines on Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism have been rev...
Source: Hamostaseologie - April 30, 2024 Category: Hematology Authors: Birgit Linnemann Jan Beyer-Westendorf Christine Espinola-Klein Katja S M ühlberg Oliver J M üller Robert Klamroth Source Type: research
Pulmonary Embolism: An Update Based on the Revised AWMF-S2k Guideline
Hamostaseologie. 2024 Apr;44(2):111-118. doi: 10.1055/s-0044-1779011. Epub 2024 Apr 30.ABSTRACTPulmonary embolism (PE) is the third most common acute cardiovascular disease. The risk of PE increases with age and mortality is high. Patients are stratified into hemodynamically stable versus unstable patients, as this has important implications for diagnosis and therapy. Since clinical signs and symptoms of acute PE are nonspecific, the clinical likelihood of PE is estimated to guide diagnostic pathways. D-dimer testing is performed in hemodynamically stable patients with low or intermediate probability of PE and the visualiz...
Source: Hamostaseologie - April 30, 2024 Category: Hematology Authors: Christian F Opitz F Joachim Meyer Source Type: research
Recurrent Venous Thromboembolism in Patients on Anticoagulation: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2024 Apr;44(2):150-154. doi: 10.1055/a-2173-7729. Epub 2024 Apr 30.ABSTRACTIn the recently updated German S2k Guideline "Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism," a new chapter was incorporated about recurrent venous thromboembolism (VTE) in patients on anticoagulation treatment. Despite the high efficacy of anticoagulation in most patients, approximately 2% experience a recurrent VTE event while receiving anticoagulant drugs. The proper diagnosis of the recurrent VTE is important and possible only with the knowledge of localization and thrombus burden of the primary VTE event. ...
Source: Hamostaseologie - April 30, 2024 Category: Hematology Authors: Robert Klamroth Hanno Riess Jan Beyer-Westendorf Birgit Linnemann Source Type: research
Aktueller Bericht der BDDH über die aktuellen gesundheitspolitischen Entwicklungen mit politischer Einordnung
Hamostaseologie. 2024 Apr;44(2):156-157. doi: 10.1055/a-2239-5959. Epub 2024 Apr 30.NO ABSTRACTPMID:38688271 | DOI:10.1055/a-2239-5959 (Source: Hamostaseologie)
Source: Hamostaseologie - April 30, 2024 Category: Hematology Authors: J ürgen Koscielny G ünther Kappert Christoph Sucker Source Type: research
Current Topics from the Revised German S2k Guideline on Diagnosis and Treatment of Venous Thromboembolism
Hamostaseologie. 2024 Apr;44(2):90-92. doi: 10.1055/a-2239-0770. Epub 2024 Apr 30.ABSTRACTIt is an honor and a great pleasure for us to be guest editors for this special issue of Hämostaseologie - Progress in Haemostasis, which addresses important issues surrounding the complex of venous thromboembolism (VTE). In February 2023, the revised guideline on "Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism" has been published on the website of the Association of the Scientific Medical Societies in Germany (AWMF)1. This guideline was drawn up under the leadership of the German Society of Angiology (DGA), and ...
Source: Hamostaseologie - April 30, 2024 Category: Hematology Authors: Birgit Linnemann Robert Klamroth Source Type: research
Thrombozyten: Blutstillung ohne Gerinnselbildung
Hamostaseologie. 2024 Apr;44(2):94. doi: 10.1055/a-2280-1098. Epub 2024 Apr 30.ABSTRACTIM VORLIEGENDEN REVIEW FASSEN R. KAISER UND KOLLEGEN BEREITS ANERKANNTE UND NEUERE STUDIEN ZUSAMMEN, DIE ERLäUTERN, WIE ES DEN KLEINEN, KERNLOSEN THROMBOZYTEN GELINGT, DIE VASKULäRE INTEGRITäT AUFRECHTZUERHALTEN, WENN SIE MIT HERAUSFORDERUNGEN WIE INFEKTIONEN, STERILEN ENTZüNDUNGEN UND SOGAR MALIGNITäT KONFRONTIERT WERDEN.PMID:38688266 | DOI:10.1055/a-2280-1098 (Source: Hamostaseologie)
Source: Hamostaseologie - April 30, 2024 Category: Hematology Source Type: research
Efgartigimod hilft bei Immunthrombozytopenie
Hamostaseologie. 2024 Apr;44(2):96. doi: 10.1055/a-2280-1083. Epub 2024 Apr 30.ABSTRACTDIE PRIMäRE IMMUNTHROMBOZYTOPENIE (ITP) IST EINE ERWORBENE AUTOIMMUNERKRANKUNG DURCH AUTOANTIKöRPER GEGEN THROMBOZYTäRE ANTIGENE UND GEKENNZEICHNET DURCH EINE ISOLIERTE THROMBOZYTOPENIE. EFGARTIGIMOD BINDET DEN FC-REZEPTOR KOMPETITIV UND BEWIRKT EINEN ABBAU UND DIE REDUKTION ZIRKULIERENDER IGG-AUTOANTIKöRPER. IN DER PHASE-3-ADVANCE-IV-STUDIE PROFITIERTEN VORBEHANDELTE ERKRANKTE MIT CHRONISCHER UND PERSISTIERENDER ITP.PMID:38688267 | DOI:10.1055/a-2280-1083 (Source: Hamostaseologie)
Source: Hamostaseologie - April 30, 2024 Category: Hematology Source Type: research
Management of Deep Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2024 Apr;44(2):97-110. doi: 10.1055/a-2178-6574. Epub 2024 Apr 30.ABSTRACTDeep vein thrombosis (DVT) and pulmonary embolism (PE) are the most common manifestations of venous thromboembolism (VTE). Most DVTs affect the lower-extremity veins. Since the symptoms of DVT are non-specific, a prompt and standardised diagnostic work-up is essential to minimise the risk of PE in the acute phase and to prevent thrombosis progression, post-thrombotic syndrome and VTE recurrence in the long-term. Only recently, the AWMF S2k guidelines on Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism have been rev...
Source: Hamostaseologie - April 30, 2024 Category: Hematology Authors: Birgit Linnemann Jan Beyer-Westendorf Christine Espinola-Klein Katja S M ühlberg Oliver J M üller Robert Klamroth Source Type: research
Pulmonary Embolism: An Update Based on the Revised AWMF-S2k Guideline
Hamostaseologie. 2024 Apr;44(2):111-118. doi: 10.1055/s-0044-1779011. Epub 2024 Apr 30.ABSTRACTPulmonary embolism (PE) is the third most common acute cardiovascular disease. The risk of PE increases with age and mortality is high. Patients are stratified into hemodynamically stable versus unstable patients, as this has important implications for diagnosis and therapy. Since clinical signs and symptoms of acute PE are nonspecific, the clinical likelihood of PE is estimated to guide diagnostic pathways. D-dimer testing is performed in hemodynamically stable patients with low or intermediate probability of PE and the visualiz...
Source: Hamostaseologie - April 30, 2024 Category: Hematology Authors: Christian F Opitz F Joachim Meyer Source Type: research
Recurrent Venous Thromboembolism in Patients on Anticoagulation: An Update Based on the Revised AWMF S2k Guideline
Hamostaseologie. 2024 Apr;44(2):150-154. doi: 10.1055/a-2173-7729. Epub 2024 Apr 30.ABSTRACTIn the recently updated German S2k Guideline "Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism," a new chapter was incorporated about recurrent venous thromboembolism (VTE) in patients on anticoagulation treatment. Despite the high efficacy of anticoagulation in most patients, approximately 2% experience a recurrent VTE event while receiving anticoagulant drugs. The proper diagnosis of the recurrent VTE is important and possible only with the knowledge of localization and thrombus burden of the primary VTE event. ...
Source: Hamostaseologie - April 30, 2024 Category: Hematology Authors: Robert Klamroth Hanno Riess Jan Beyer-Westendorf Birgit Linnemann Source Type: research
